News

Filter

Current filters:

trebananib

Amgen's trebananib meets primary end-point in Ph III study of recurrent ovarian cancer

13-06-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, has announced that the…

AmgenBiotechnologyOncologyResearchtrebananib

Back to top